Structural Basis for Penetration of the Glycan Shield of Hepatitis C Virus E2 Glycoprotein by a Broadly Neutralizing Human Antibody

被引:61
作者
Li, Yili [1 ,2 ]
Pierce, Brian G. [1 ]
Wang, Qian [1 ,2 ]
Keck, Zhen-Yong [3 ]
Fuerst, Thomas R. [1 ,2 ]
Foung, Steven K. H. [3 ]
Mariuzza, Roy A. [1 ,2 ]
机构
[1] Univ Maryland, Inst Biosci & Biotechnol Res, WM Keck Lab Struct Biol, Rockville, MD 20850 USA
[2] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA
[3] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94304 USA
基金
美国国家卫生研究院;
关键词
Antibody; Crystal Structure; Glycosylation; Hepatitis C Virus (HCV); Vaccine; Neutralization; HUMAN MONOCLONAL-ANTIBODIES; ENVELOPE GLYCOPROTEIN; AMINO-TERMINUS; PROTEIN; BINDING; INFECTION; GLYCOSYLATION; EPITOPES; ENTRY; CD81;
D O I
10.1074/jbc.M115.643528
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma. A challenge for HCV vaccine development is to identify conserved epitopes able to elicit protective antibodies against this highly diverse virus. Glycan shielding is a mechanism by which HCV masks such epitopes on its E2 envelope glycoprotein. Antibodies to the E2 region comprising residues 412-423 (E2(412-423)) have broadly neutralizing activities. However, an adaptive mutation in this linear epitope, N417S, is associated with a glycosylation shift from Asn-417 to Asn-415 that enables HCV to escape neutralization by mAbs such as HCV1 and AP33. By contrast, the human mAb HC33.1 can neutralize virus bearing the N417S mutation. To understand how HC33.1 penetrates the glycan shield created by the glycosylation shift to Asn-415, we determined the structure of this broadly neutralizing mAb in complex with its E2(412-423) epitope to 2.0 resolution. The conformation of E2(412-423) bound to HC33.1 is distinct from the -hairpin conformation of this peptide bound to HCV1 or AP33, because of disruption of the -hairpin through interactions with the unusually long complementarity-determining region 3 of the HC33.1 heavy chain. Whereas Asn-415 is buried by HCV1 and AP33, it is solvent-exposed in the HC33.1-E2(412-423) complex, such that glycosylation of Asn-415 would not prevent antibody binding. Furthermore, our results highlight the structural flexibility of the E2(412-423) epitope, which may serve as an immune evasion strategy to impede induction of antibodies targeting this site by reducing its antigenicity.
引用
收藏
页码:10117 / 10125
页数:9
相关论文
共 60 条
[1]  
Angus AGN, 2011, FUTURE MICROBIOL, V6, P279, DOI [10.2217/FMB.11.9, 10.2217/fmb.11.9]
[2]   Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes [J].
Bankwitz, Dorothea ;
Steinmann, Eike ;
Bitzegeio, Julia ;
Ciesek, Sandra ;
Friesland, Martina ;
Herrmann, Eva ;
Zeisel, Mirjam B. ;
Baumert, Thomas F. ;
Keck, Zhen-yong ;
Foung, Steven K. H. ;
Pecheur, Eve-Isabelle ;
Pietschmann, Thomas .
JOURNAL OF VIROLOGY, 2010, 84 (11) :5751-5763
[3]   GlyProt:: in silico glycosylation of proteins [J].
Bohne-Lang, A ;
von der Lieth, CW .
NUCLEIC ACIDS RESEARCH, 2005, 33 :W214-W219
[4]   Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C Virus [J].
Broering, Teresa J. ;
Garrity, Kerry A. ;
Boatright, Naomi K. ;
Sloan, Susan E. ;
Sandor, Frantisek ;
Thomas, William D., Jr. ;
Szabo, Gyongyi ;
Finberg, Robert W. ;
Ambrosino, Donna M. ;
Babcock, Gregory J. .
JOURNAL OF VIROLOGY, 2009, 83 (23) :12473-12482
[5]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[6]   Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study [J].
Chung, R. T. ;
Gordon, F. D. ;
Curry, M. P. ;
Schiano, T. D. ;
Emre, S. ;
Corey, K. ;
Markmann, J. F. ;
Hertl, M. ;
Pomposelli, J. J. ;
Pomfret, E. A. ;
Florman, S. ;
Schilsky, M. ;
Broering, T. J. ;
Finberg, R. W. ;
Szabo, G. ;
Zamore, P. D. ;
Khettry, U. ;
Babcock, G. J. ;
Ambrosino, D. M. ;
Leav, B. ;
Leney, M. ;
Smith, H. L. ;
Molrine, D. C. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (04) :1047-1054
[7]   Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization [J].
Deng, Lu ;
Ma, Li ;
Virata-Theimer, Maria Luisa ;
Zhong, Lilin ;
Yan, Hailing ;
Zhao, Zhong ;
Struble, Evi ;
Feinstone, Stephen ;
Alter, Harvey ;
Zhang, Pei .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (29) :10690-10695
[8]   Mutations within a Conserved Region of the Hepatitis C Virus E2 Glycoprotein That Influence Virus-Receptor Interactions and Sensitivity to Neutralizing Antibodies [J].
Dhillon, Simrat ;
Witteveldt, Jeroen ;
Gatherer, Derek ;
Owsianka, Ania M. ;
Zeisel, Mirjam B. ;
Zahid, Muhammad N. ;
Rychlowska, Malgorzata ;
Foung, Steven K. H. ;
Baumert, Thomas F. ;
Angus, Allan G. N. ;
Patel, Arvind H. .
JOURNAL OF VIROLOGY, 2010, 84 (11) :5494-5507
[9]   Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C Virus [J].
Dowd, Kimberly A. ;
Netski, Dale M. ;
Wang, Xiao-Hong ;
Cox, Andrea L. ;
Ray, Stuart C. .
GASTROENTEROLOGY, 2009, 136 (07) :2377-2386
[10]   Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry [J].
Evans, Matthew J. ;
von Hahn, Thomas ;
Tscherne, Donna M. ;
Syder, Andrew J. ;
Panis, Maryline ;
Woelk, Benno ;
Hatziioannou, Theodora ;
McKeating, Jane A. ;
Bieniasz, Paul D. ;
Rice, Charles M. .
NATURE, 2007, 446 (7137) :801-805